|
|
Article: New Study Comparing Weekly Osteoporosis Treatments Shows FOSAMAX Demonstrated Significantly Greater Increases in Bone Mineral Density and Reductions in Markers of Bone Turnover than Actonel.
- Article from:
- Business Wire
- Article date:
- September 28, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WHITEHOUSE STATION, N.J. -- FOSAMAX Maintained or Increased BMD at Hip and Spine for Significantly More Patients than Actonel, with Similar Tolerability, in this 12 Month Study
FOSAMAX(R) Once Weekly (alendronate sodium) increased bone mineral density (BMD) more than Actonel(R) Once-a-Week (risedronate) with similar tolerability, according to results of the FOSAMAX Actonel Comparison Trial (FACT). This is the first U.S. head-to-head study comparing FDA approved once weekly osteoporosis treatments in postmenopausal women with osteoporosis. In this study, FOSAMAX provided greater increases in BMD at all sites measured as early as six months, and lowered levels of ...